Non classé

Alexandra CARREL and Mathilde SALAVIN would be delighted to see you at the BIO International Convention in Boston from 5th & 8th June!

Fix a date with Alexandra via the BIO platform or let us know when you’re there.
Have a great convention !

#BIO2023
#FrenchHealthcare

Alexandra Carrel, Jeremy Pappalardo and the MCE CARREL team are pleased to announce the appointment of Mathilde Salavin as Partner.

Based in Lyon, Mathilde Salavin works with a number of startup clients and public institutions in all areas of health and digital rights. Her practice covers the management of the clinical development of their drugs and devices as well as the negotiation of intellectual property contracts related to the transfer of their technologies.

She also regularly works alongside the firm’s private equity teams on contractual audit assignments.

Mathilde Salavin began her career in 2006 at SANOFI. She then moved within the group, before taking a position as legal manager within SANOFI Pasteur in 2014. She joined MCE Carrel in 2020 and participated in the opening of the Lyon office.

Mathilde will continue to bring her experience and expertise to our clients’ innovation projects.

Mathilde Salavin’s association with MCE CARREL AVOCATS is in line with the development policy and the dynamic approach desired by the firm to continue to be among the key legal players in the world of health, innovation and biotechnology.

Alexandra CARREL, Jeremy PAPPALARDO and the MCE CARREL Team are pleased to welcome a new colleague who brings a wealth of experience to the firm :

Armand DELIEGE

Armand joined the firm in April 2022 after more than 11 years as a contract & IP lawyer for a SATT and a national innovation research institute. Specialized in health and pharmaceutical law, NTIC and electronics, Armand has notably accompanied innovative projects from academic laboratories to the market, drafting and negotiating contracts in French and English. His training in international and European law is immensely relevant.

We wish Armand a very warm welcome.

MCE CARREL is pleased to have assisted GNUBIOTICS in its negotation with ADM on their Strategic Partnership in Microbiome Innovation.

For the full story : GNUBIOTICS Press release

MCE CARREL Avocats is very pleased to announce the promotion of Jeremy PAPPALARDO to partner of the firm as of January 1, 2022, alongside Alexandra CARREL. The whole team congratulates him on his appointment and wishes him every success.

A member of the firm since 2017, Jeremy specialises in Life Sciences Innovation and Digital. His clients include research institutes, SATTs, e-health start-ups and biotech companies. Jeremy’s promotion is a new milestone in the development of MCE CARREL, to which he has continuously contributed since its creation.

Cabinet Carrel assisted VECT-HORUS S.A.S. (Marseille, France) in the negotiation of a collaboration and licensing agreement with ONO Pharmaceutical Co. (Osaka, Japan)

VECT-HORUS ENTERS INTO COLLABORATION AND LICENSE AGREEMENT WITH ONO PHARMACEUTICAL CO., LTD.

2019/03/26

Vect-Horus S.A.S. (Marseille, France) announced today that Vect-Horus and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration and license agreement, focused on the development of novel molecules targeting neurodegenerative diseases.

Under the agreement, Vect-Horus will receive research fees, success-based milestones on the research and development progress, as well as royalties on sales of the products.

Vect-Horus will apply its proprietary VECTrans® technology, which facilitates the transport of drugs into the brain, to ONO’s therapeutic molecules. Vect-Horus will utilize its expertise to conjugate these therapeutic molecules with its peptide vectors and demonstrate improved brain uptake and efficacy in animals. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.

“We are delighted to partner with Ono, one of the oldest pharmaceutical companies in the world and an important developer of innovative drugs,” commented Alexandre Tokay, Chief Executive Officer and cofounder of Vect-Horus. “Our agreement with Ono strengthens our long-standing commitment to improve, using our technology, the brain delivery of therapeutic molecules and bring forward novel therapies that address critical unmet needs.”

About Vect-Horus Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (including the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more about Vect-Horus, visit www.vect-horus.com. For more information about this press release, please contact Elodie Dormes, Business Development Manager of Vect-Horus: contact@vect-horus.com.